Cullinan Therapeutics CGEM
NASDAQ CGEM
$22.09 -0.07 (-0.32%)
As of: Sep 4, 2026 · 3:59 PM EDT

Cullinan Therapeutics (CGEM) EBT Margin (2021)

Cullinan Therapeutics (CGEM) posted quarterly EBT Margin of 7.49% for Q1 2021.

Analysis

Cullinan Therapeutics (CGEM) EBT Margin (2021) Analysis & Trends

Cullinan Therapeutics' EBT Margin history runs 1 years deep, the most recent figure standing at 7.49% for Q1 2021.

  • In Q1 2021, EBT Margin changed N/A year-over-year to 7.49%; the TTM figure through Dec 2021 stood at 356.25% (changed N/A YoY), while the FY2021 annual figure was 356.25%, changed N/A from the prior year.
  • EBT Margin for Q1 2021 stood at 7.49%.
  • The five-year high for EBT Margin was 7.49% in Q1 2021, with the low at 7.49% in Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 41.75%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 35.61%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 35.78%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -528.97%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 18.33%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 13.77%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 12.09%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -2.67%
10 Cullinan Therapeutics 1.37 Bn 1.37 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 7.49%